Intelligent Bio Solutions Says It Completed 135-Participant Method Comparison Study, Concluding All Clinical Data Collection For FDA 510(k) Submission Targeted In H2 2026
A company finished testing a medical device with 135 people and collected all the data they need to ask the FDA for permission to sell it—they're planning to ask sometime in the second half of 2026. When a company finishes a big study step like this, it shows they're moving forward on their plan, though it's still early in the approval process.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.